Study summary · research use only
Vasoactive intestinal peptide: a direct renal natriuretic substance
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This study in seven conscious male rabbits compared natriuretic and haemodynamic responses to vasoactive intestinal peptide (VIP), infused intravenously (10(-4)-100 pmol min-1 kg-1) versus directly into the renal artery, to test whether VIP acts directly on the kidney. The abstract reports VIP significantly affected the renal circulation without changing systemic arterial pressure or pulse rate, producing a significant fall in renal plasma flow and glomerular filtration rate and a significant rise in renal vascular resistance with both renal and intravenous infusion. Despite a significant decline in filtered sodium load, intrarenal VIP infusion was associated with a significant log dose-related increase in fractional sodium excretion. The authors describe VIP's actions on intrarenal vessels and tubules as direct, leading to increased renal vascular resistance and sodium excretion.
Abstract
To establish whether or not vasoactive intestinal peptide (VIP) acts directly on the kidney and also to define the renal responses to it, we compared the natriuretic and haemodynamic responses to VIP (10(-4)-100 pmol min-1 kg-1) infused intravenously with those obtained by direct infusion into the renal artery in seven conscious male rabbits. VIP had significant effects on the renal circulation without changing systemic arterial pressure or pulse rate. There was a significant fall from control in effective renal plasma flow (P less than 0.05 renal infusion, P less than 0.01 intravenous infusion) and glomerular filtration rate (P less than 0.01 renal, P less than 0.05 intravenous). The derived renal vascular resistance rose significantly from control (P less than 0.01 renal, P less than 0.01 intravenous). Despite the significant decline in filtered sodium load (P less than 0.01 renal, P less than 0.001 intravenous), there was a significant log dose-related increase in fractional sodium excretion (P less than 0.005) with intrarenal infusion of VIP. We conclude that the actions of VIP on intrarenal blood vessels and renal tubules are direct, leading to increases in renal vascular resistance and fractional sodium excretion.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.